Sweden
· Delayed Price · Currency is SEK AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of SEK 2.15 trillion. The enterprise value is 2.43 trillion.
| Market Cap | 2.15T |
| Enterprise Value | 2.43T |
Important Dates
The last earnings date was Tuesday, November 12, 2024.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | Aug 8, 2024 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.22% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.54B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.61, with an EV/FCF ratio of 24.99.
| EV / Earnings | 36.91 |
| EV / Sales | 4.59 |
| EV / EBITDA | 12.61 |
| EV / EBIT | 17.22 |
| EV / FCF | 24.99 |
Financial Position
The company has a current ratio of 0.93, with a Debt / Equity ratio of 0.77.
| Current Ratio | 0.93 |
| Quick Ratio | 0.71 |
| Debt / Equity | 0.77 |
| Debt / EBITDA | 1.69 |
| Debt / FCF | 3.30 |
| Interest Coverage | 10.12 |
Financial Efficiency
Return on equity (ROE) is 16.66% and return on invested capital (ROIC) is 12.28%.
| Return on Equity (ROE) | 16.66% |
| Return on Assets (ROA) | 8.50% |
| Return on Capital (ROIC) | 12.28% |
| Revenue Per Employee | 5.78M |
| Profits Per Employee | 732,752 |
| Employee Count | 89,900 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 1.63 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +2.70% in the last 52 weeks. The beta is 0.17, so AstraZeneca's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | +2.70% |
| 50-Day Moving Average | 1,555.78 |
| 200-Day Moving Average | 1,572.31 |
| Relative Strength Index (RSI) | 31.80 |
| Average Volume (20 Days) | 460,404 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AstraZeneca had revenue of SEK 519.35 billion and earned 65.87 billion in profits. Earnings per share was 42.09.
| Revenue | 519.35B |
| Gross Profit | 429.01B |
| Operating Income | 138.68B |
| Pretax Income | 80.35B |
| Net Income | 65.87B |
| EBITDA | 186.53B |
| EBIT | 138.68B |
| Earnings Per Share (EPS) | 42.09 |
Balance Sheet
The company has 50.00 billion in cash and 320.63 billion in debt, giving a net cash position of -270.63 billion.
| Cash & Cash Equivalents | 50.00B |
| Total Debt | 320.63B |
| Net Cash | -270.63B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 413.86B |
| Book Value Per Share | 266.44 |
| Working Capital | -17.96B |
Cash Flow
In the last 12 months, operating cash flow was 114.95 billion and capital expenditures -17.66 billion, giving a free cash flow of 97.30 billion.
| Operating Cash Flow | 114.95B |
| Capital Expenditures | -17.66B |
| Free Cash Flow | 97.30B |
| FCF Per Share | n/a |
Margins
Gross margin is 82.61%, with operating and profit margins of 26.70% and 12.68%.
| Gross Margin | 82.61% |
| Operating Margin | 26.70% |
| Pretax Margin | 15.47% |
| Profit Margin | 12.68% |
| EBITDA Margin | 35.92% |
| EBIT Margin | 26.70% |
| FCF Margin | 18.73% |
Dividends & Yields
AstraZeneca does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | 3.66% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 71.25% |
| Buyback Yield | -0.22% |
| Shareholder Yield | -0.22% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AstraZeneca has an Altman Z-Score of 3.02.
| Altman Z-Score | 3.02 |
| Piotroski F-Score | n/a |